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Objectives: The aim of this study was to examine the outcome of surgical treatment of acute limb
ischaemia (ALI) developing in the presence of malignancy.
Methods: Patients undergoing emergency surgery were identiﬁed from theatre registers, notes were
reviewed, and data collected in relation to indications for, and outcome following operation. All patients
with a current or past medical history of histologically conﬁrmed malignant disease were identiﬁed and
their notes speciﬁcally reviewed to determine the staging of their tumours. The results of the malignancy
cohort were compared to a group of patients undergoing surgery for ALI of other aetiologies.
Results: Fourteen patients with a malignancy were identiﬁed with ALI and in addition there were 102
without malignancy. The cohort with a malignancy contained a higher proportion of males (p¼ 0.0305),
and a greater number of smokers (p¼ 0.037) than those with other aetiologies for ALI. The peri-operative
management of the 2 groups was similar. Histological examination revealed tumour thrombus in only 1
case. The recurrence (29% versus 18%; p¼ 0.328) and amputation rates (29% versus 17%; p¼ 0.278) were
similar, however, the 30-day (50% versus 30%; p¼ 0.038) and 60-day mortality rates (100% versus 35%;
p< 0.001) were signiﬁcantly higher in the malignancy group.
Conclusions: The development of ALI in patients with malignant disease may be regarded as a terminal
event despite comparable performance status at the time of surgery to those with other cause for ALI.
The role of surgery in patients with known advanced malignancies appears to be of dubious beneﬁt with
little survival beneﬁt.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
The link between thrombosis and malignancy was ﬁrst docu-
mented by Armand Trousseau in 1865 when he reported that
unexpected migratory thrombophlebitis may be an indicator of an
occult visceral malignancy, the so called Trousseau syndrome.1 The
deﬁnition was expanded by Sack et al. 2 and it now includes
patients with known malignancies who develop thromboses in
arterial or venous systems. The condition has a complex multifac-
torial aetiology reviewed extensively by Varki.3
When a patient attends with an ALI, it is imperative to proceed
urgently to attempt revascularisation so as tomaximise the chances
of limb salvage. In this setting, there may be little opportunity to
screen for tumours but if a history of active malignancy is reported
then this may inﬂuence the subsequent management.
There is currently little data relating to the management of an
ALI in patients with concurrent malignant disease. The aim of thisycoed, Pontypridd, Rhondda
4 1443 650625.
. Morris-Stiff).
iates Ltd. Published by Elsevier Ltstudy was to compare the outcomes of surgery for ALI in patients
with an active malignancy and those with other aetiologies.2. Patients and methods
All patients undergoing emergency arterial surgery for ALI during
the period 1993 to 2003 were identiﬁed from the prospectively
maintained theatre register. Only patients inwhoman embolectomy
was attempted on a native artery were included and those who had
occluded vascular graft were excluded. The case noteswere assessed
and data retrieved in relation to: demographic features, patient
history and risk factors for limb ischaemia; investigations; peri-
operative management; and outcome including postoperative
complications. In addition ahistoryof past or concurrentmalignancy
was sought through review of notes and both radiology and
pathologydepartment computeriseddatabases, thesepatientsbeing
identiﬁed as a subgroup. For this group, the tumour origin, histo-
logical type and stage were recorded. The malignancy group was
compared to the remainder of the cohort undergoing surgery for ALI.
Comparison of proportions was by the Chi-squared test and
categorical data by means of the Student’s t test with statistical
signiﬁcance taken at the 5% level.d. All rights reserved.
Table 1
Comparison of the demographic details of patients with malignancy and atrial
ﬁbrillation as the aetiological factors for acute limb ischaemia.
Malignancy Other Signiﬁcance
Age SEM (range) 71.5 8 (47–83) 72.9 13 (43–99) p¼ 0.684
Gender – M:F 9:5 35:67 p¼ 0.037
ASA score (%) – 2:3:4 43:36:21 41:52:9 p¼ 0.287
History of smoking 64% 37% p¼ 0.037
ASA¼American Society of Anesthesiologists.
Table 2
Peri-operative investigation and management.
Perioperative Factors Malignancy
n¼ 14
Other
n¼ 102
Signiﬁcance
Preoperative imaging (%) 64 44 p¼ 0.156
Preoperative heparinization (%) 86 79 p¼ 0.579
Prophylactic antibiotics (%) 57 61 p¼ 0.196
Local anaesthesia (%) 43 41 p¼ 0.849
Bypass surgery performed (%) 7 10 p¼ 0.750
Median delay prior to
embolectomy
17 hr 23 hr p¼ 0.953
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During the interval covered by the study, 116 patients under-
went emergency vascular surgery for ALI of which 14 (12%) had or
were subsequently diagnosed with a malignancy.
The underlying malignancies were bronchial adenocarcinoma
(n¼ 4); transitional cell carcinoma bladder (n¼ 2); lymphoma
(n¼ 2); oesophageal adenocarcinoma (n¼ 2); bronchial squamous
cell carcinoma (n¼ 1); colonic adenocarcinoma (n¼ 1); pancreatic
adenocarcinoma (n¼ 1); gastric adenocarcinoma (n¼ 1); vulval
squamous cell carcinoma (n¼ 1); and chronic lymphatic leukaemia
(n¼ 1). In 4 cases, patients had known malignancies, and in 10
cases tumours were diagnosed at the time of admission with ALI
following surgery or shortly thereafter.
The demographic features are summarised in Table 1. Patients
with malignancies were predominantly males (p¼ 0.030). The
mean age and distribution of patients according to ASA grade was
comparable in the 2 groups. However, the proportion of smokers
was signiﬁcantly higher in the malignancy group (p¼ 0.037).
The peri-operative management of the 2 groups is summarised
in Table 2. The delay from ﬁrst presentation to surgery was similar
for the 2 groups. All aspects of investigation andmanagement were
comparable for the 2 study groups including use of preoperative
imaging, preoperative heparinisation and antibiotic use. Imaging
studies were performed in 9 of 14 patients in the malignancy group
pre-operatively and a further 2 patients underwent intra-operative
angiography. Only 1 patient had signiﬁcant arterial disease and
underwent a concurrent bypass procedure. In the non-malignancy
ALI group, 10 patients had underlying vascular disease which was
felt to be contributory to the ALI and underwent bypass surgery.
Histological examination of specimens removed from patients
with a malignancy identiﬁed carcinoma cells in 1 patient with
a colonic adenocarcinoma.
The outcomes of surgery are summarised in Table 3. The overall
complication rates were comparable in the 2 groups. The rates of
recurrent emboli for patients withmalignancy were higher than for
those with other causes of ALI but not signiﬁcantly so (29% versus
18%; p¼ 0.328). The requirement for subsequent amputation was
also higher but again not signiﬁcantly so (29% versus 17%;
p¼ 0.278).
The 30-day mortality rate was signiﬁcantly higher in the
malignancy group (50% versus 30%; p¼ 0.038). When the period of
assessment was extended to 60 days, all those with a malignancy
had died and the difference was more signiﬁcant (100% versus 35%;
p< 0.001).Table 3
Outcome following embolectomy.
Postoperative Complications Malignancy n¼ 14 Other n¼ 102 Signiﬁcance
Complications (%) 64 61 p¼ 0.855
Recurrence (%) 29 18 p¼ 0.328
Amputation (%) 29 17 p¼ 0.278
30-day mortality (%) 50 30 p¼ 0.143
60-day mortality (%) 100 35 p< 0.0014. Discussion
The primary ﬁnding of this observational study is that patients
withmalignant disease undergoing emergency surgery for ALI have
a signiﬁcantly poorer outcome than other patients with ALI
undergoing surgery who were of similar age and comorbid status.
This was manifested in terms of a higher rate of a higher post-
operative mortality rate both at 30 and 60 days.There are two potential causes of ALI in patients with malig-
nancy. Likely to be the most common and probably under-
documented is in relation to a paraneoplastic syndrome,
however, case series of embolectomy rarely mention this aetiology.
The occurrence of ALI in acute myeloid leukaemia has been well-
documented.4 A detailed review of the literature identiﬁed only
two case series speciﬁcally assessing emboli arising in patients with
malignancy.5,6 Rigdon reported 3 patients with malignancy-related
hypercoagulability related to tumours of the breast, lung and
pancreas.5 El Sakka and colleagues reviewed all patients with
critical limb ischaemia reporting to their unit of an 18-month
period and found occult malignancies in 10 of 62 (16%) of those
presenting acutely and 12 of 130 (9.2%) of patients with chronic
symptoms.6 They also reported 50%mortality at 6 months for those
with a malignancy compared to 20.6% in those with no tumour
present.
The second source of emboli is from the tumour itself and whilst
numerically an uncommon cause of ALI, its novel nature makes it
the subject of a greater body of literature with numerous case
reports. The commonest source of tumour emboli is left-sided atrial
myxomass and in 20% presentation is with symptoms related to
distal embolisation.7 Morasch and Shanik noted 20 case reports/
series containing a total of 70 patients with non-myxomatous
tumour emboli in addition to their own case in their literature
review in 2003.8 However, in a collective assessment of over 1500
embolectomies only 6 cases of tumour emboli were identiﬁed.9–11
In this series, only 1 patient had malignant tissue identiﬁed on
histological examination of the embolic material.
In the current series it is presumed that the occlusions were due
to thrombosis occurring as part of a paraneoplastic syndrome as
only 1 patient had signiﬁcant vascular disease in the vessel segment
containing the occlusion. The origin of the adenocarcinoma cells in
the patient inwhom thesewere identiﬁed is unclear as thesewould
have expected to have traversed the portal system to the liver and
not be present in the systemic circulation.
Despite the small volume of papers discussing the risks of
arterial embolism in malignancy, there is a large volume of litera-
ture in relation to venous thrombosis developing in the presence of
neoplastic disease. Although the precise mechanism is uncertain,
and probably multifactorial, it is commonly said to be related to
a paraneoplastic syndrome.3,12 There is an overall increased risk for
venous thrombosis in the order of 4-fold in patients withmalignant
disease, increasing to 6-fold in patients receiving chemotherapy.13
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include adenocarcinomas of the lung, stomach and pancreas14
although increased risk has also been documented for tumours
prostate, colon, brain, breast and ovary.15,16
In the current series, 4 of the patients were known to have
malignant tumour at the time of presentation with an ALI and the
remainder was diagnosed following the embolectomy, in a Trous-
seau-type presentation.
The management of malignancy-related thrombo-embolic
disease, in addition to removal of the embolus itself and treatment
of the underlying neoplasm, should include treatment with heparin
as there is evidence that this may exert anti-tumour effect in
addition to an anti-thrombotic effect.17,18,19 In this series, 86% of
patients eventually diagnosed with malignant disease had been
heparinised preoperatively and all received post-embolectomy
heparin therapy.
Limitations of the current study include the fact that given the
nature of the study, therewas no quality of life assessment and thus
it may be argued that an operation may have beneﬁted the patient
in terms of pain relief. However, given the signiﬁcant recurrence
rates, amputations and subsequent mortality any beneﬁt would be
short term. A further limitation in terms of deﬁning the extent of
the problemwas that data were only available on those undergoing
surgery and thus the number of patients unﬁt and not referred for
surgical assessment.
5. Conclusions
The performance of emergency vascular surgery for patients with
advanced malignant disease would appear to be of limited beneﬁt.
Indeed, in caseswhere patients are known to havemetastatic disease
at the time of presentation with ALI, it may be advocated that oper-
ative intervention is not undertaken as it is clear that the peri-
operative mortality and subsequent survival are poor. In patients
with ALI in whom no speciﬁc aetiological factor is identiﬁed, a diag-
nosis of underlying malignancy should be considered.
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